Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sonnenberg, G. E
Right arrow Articles by Reinhardt, R. R
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Drug treatments for obesity: where are we heading and how do we get there?

Gabriele E Sonnenberg

Clinical Pharmacology and Research, Novo Nordisk Inc.,100 College Road West, Princeton, New Jersey 08540, USA, gsnn{at}novonordisk.com

Glenn Matfin

Clinical Pharmacology and Research, Novo Nordisk Inc.,100 College Road West, Princeton, New Jersey 08540, USA

Rickey R Reinhardt

Clinical Pharmacology and Research, Novo Nordisk Inc.,100 College Road West, Princeton, New Jersey 08540, USA

Obesity has reached epidemic proportions with an estimated 1.7 billion people worldwide classified as either overweight or obese. Obesity is associated with multiple co-morbidities (often clustered as the metabolic syndrome), and can result in decreased life expectancy, with enormous costs to society. Even modest weight loss has been demonstrated to exhibit beneficial effects on the co-morbidities of obesity. While reduced caloric intake and increased physical activity, combined with behavioural modification, appears to be the most rational approach to weight reduction, it only offers short-lived success. For severely obese individuals, bariatric surgery has become an increasingly preferred option resulting in dramatic and well-maintained weight reductions followed by significant changes in obesity-related diseases.

Currently, few anti-obesity drugs are approved by regulatory authorities for long-term use (i.e. orlistat, sibutramine and rimonabant). Anti-obesity drug development is an active and dynamic field focusing on two major approaches: 1) inhibiting energy intake by addressing the input into the hypothalamic feeding centre or, 2) attempting to accelerate energy expenditure. Overcoming the hurdles of developing such medications is a daunting task, but it can be anticipated that several drugs in current development might become available within the next decade, and combination therapy of two or more agents could be the future of pharmacological prevention and treatment of obesity.

Key Words: anti-obesity drugs • bariatric surgery • diabetes • metabolic syndrome • obesity

References

  • Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. Available at: http://www.cdc.gov/nchs/about/major/nhanes/datalink.htm
  • Flegal KM, Carroll MD, Ogden CL, Johnson CL Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-7.[Abstract/Free Full Text]
  • Ogden CL, Carroll MD, Curtin LR et al. Prevalence of Overweight and Obesity in the United States, 1999-2004. JAMA 2006;295:1549-55.[Abstract/Free Full Text]
  • Peeters A., Barendregt JJ, Willekens F. et al. Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis. Ann Intern Med 2003;138:24-32.[Abstract/Free Full Text]
  • Mokdad A., Marks J., Stroup D., Gerberding J. Correction: Actual Causes of Death in the United States, 2000 JAMA 2005;293:293-4.[Free Full Text]
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP, Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
  • World Health Organization. Report of a WHO consultation on obesity. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization,1998. Available at: who.int/home/info.html
  • Yusuf S., Hawken S., Ôunpuu S., on behalf of the INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Alberti Kgmm, Zimmet P., Shaw J. Metabolic syndrome - a new worldwide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.[CrossRef][Medline] [Order article via Infotrieve]
  • Small CJ, Bloom SR The therapeutic potential of gut hormone peptide YY3-36 in the treatment of obesity. Expert Opinion Invest Drugs 2005;14:647-53.[CrossRef]
  • Small CJ, Parkinson JR, Bloom SR Novel therapeutic targets for appetite regulation. Current Opinion Invest Drugs 2005;6:369-72.
  • Black, SC Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drug 2004;5:389-94.[Medline] [Order article via Infotrieve]
  • Ravinet Trillou C., Delgorge C., Menet C. et al. Cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28:640-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kissebah AH, Krakower GR Regional adiposity and morbidity. Physiol Rev 1994;74:761-811.[Free Full Text]
  • Kissebah AH, Krakower GR, Sonnenberg GE, Hennes MMI. Clinical manifestations of the metabolic syndrome. In: Handbook of Obesity. Bray GA, Bouchard C, James WPT, editors. Marcel Dekker, Inc.New York;1997:601-36.
  • Brochu M., Tchernof A., Dionne IJ et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab 2001; 86:1020-5.[Abstract/Free Full Text]
  • Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 1995;3:S211-S216.[Medline] [Order article via Infotrieve]
  • Wadden TA, Anderson DA, Foster GD Two-year changes in lipids and lipoproteins associated with the maintenance of a 5-10% reduction in initial weight: some findings and some questions. Obes Res 1999;7:170-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Singh RB, Rastogi SS, Verma R. et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992;304:1015-19.[Abstract/Free Full Text]
  • Knowler WC, Barrett-Connor E., Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
  • Thorogood M., Hillsdon M., Summerbell C. Changing behaviour. Clinical Evidence 2002;6:31-49.
  • Bravata DM, Sanders L., Huang J. et al. Efficacy and safety of low carbohydrate diets: a systematic review. JAMA 2003;289:1837-50.[Abstract/Free Full Text]
  • Freedman MR, King J., Kennedy E. Popular diets: A scientific review. Obes Res 2001;9:S1-S40.[Web of Science]
  • Astrup A., Grunwald GK, Melanson EL et al. The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes Relat Metab Disord 2000;24:1545-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med 1991;115:956-61.[Abstract/Free Full Text]
  • Buchwald, H. Consensus Conference Statement Bariatric surgery for morbid obesity: Health implications for patients, health professionals, and third-party payers. Obes Surg Relat Dis 2005;1:371-81.[CrossRef]
  • Torgerson JS, Hauptman J., Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.[Abstract/Free Full Text]
  • Padwal R., Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes 2003;27:1437-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Padwal RS, Majundar SR Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bays HE Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004;12:1197-211.[Web of Science][Medline] [Order article via Infotrieve]
  • DiMasi JA, Hansen RW, Grabowski HG The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22:151-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Food and Drug Administration (FDA): Guidance for Industry Developing Products for Weight Management, 14th February 2007. Available at: http://www.fda.gov/cder/guidance/7544dft.pdf. (Accessed 17th March 2007).
  • Committee for medicinal products for human use (CHMP): guideline on clinical investigation of medicinal products used in weight control available at: http://www.emea.europa.eu/pdfs/human/ewp/028196en.pdf. (Accessed 17th March 2007).
  • Sjöström L., Lindroos AK, Peltonen M. et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-9.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 3, 111-117 (2007)
DOI: 10.1177/14746514070070030301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
G. Matfin
Aspects of drug development and clinical trials -- Part 2
The British Journal of Diabetes & Vascular Disease, July 1, 2007; 7(4): 149 - 150.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sonnenberg, G. E
Right arrow Articles by Reinhardt, R. R
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?